Enlivex Therapeutics

About Enlivex Therapeutics

Enlivex (Nasdaq: ENLV) is a macrophage reprogramming biotech. In January 2026, the company pioneered a unique 'Digital Asset Treasury' strategy centered on the RAIN token, becoming the first U.S.-listed public company to provide direct exposure to decentralized prediction markets while continuing late-stage clinical development of Allocetra™.